350 articles in this topic
A novel endoluminal device implanted in the gut improved insulin sensitivity and weight control beyond what semaglutide achieved in a pig model.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
Three NIH-funded studies this week tackle metabolic decline, cardiac risk, and brain tumors — all with aging implications.
A major Cochrane network meta-analysis protocol will rank all insulin regimens by efficacy and safety for adults with type 1 diabetes.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
Wearable microneedle patches tap interstitial fluid to monitor glucose, lactate, and electrolytes in real time — no needles, no lab.
Master the advanced molecular architecture of AMPK — from isoform-specific signaling and spatial compartmentalization to emerging pharmacological strategies targeting the energy sensor at the heart of longevity biology.
Go deeper into how AMPK detects energy stress, activates upstream kinases, and coordinates metabolism, autophagy, and longevity pathways at the molecular level.
Researchers mapped how anesthetics, nitric oxide, and other drugs alter hemoglobin's grip on oxygen — with real implications for critical care.
Foundayo (orforglipron) becomes the first oral GLP-1 receptor agonist approved for obesity, offering a pill alternative to injectable Wegovy.
